EXOSOME DIAGNOSTICS PIPELINE PROGRESSING The Company’s first exosome diagnostic collaboration with the University of Queensland (UQ) to develop an exosome ovarian cancer screening test delivered data from an equivalence study showing that EXO-NET was effective for capturing exosomes from serum or plasma. Subsequently, a biomarker validation study commenced to evaluate the test in 500-samples with a data read-out expected by December 2024. INOVIQ plans to expand its exosome diagnostic program over the next 12-months through collaborations with academic, diagnostic and therapeutic companies for liquid biopsies and companion diagnostics. 3 Annual Report 2024 Dr Leearne Hinch CEO EARLY-STAGE EXOSOME THERAPEUTICS PROGRAM INOVIQ is developing exosome therapeutics engineered to target and kill cancer. This groundbreaking program builds on our innovative exosome diagnostic work. INOVIQ has leveraged its proprietary exosome platform, in-house capabilities and expertise in exosome science to commence an in-house exosome therapeutics program. The Company has established core capabilities to engineer, load and produce exosomes for therapeutic applications. Proof-of-concept data highlighted the potential of INOVIQ’s immune-cell derived CAR-exosomes as an effective cancer therapy and the potential for RNA drug-loaded exosome therapeutics. The Company is scaling its exosome production capacity using its proprietary EXOACE technology to isolate exosomes and is advancing its CAR-exosome program towards key preclinical in vitro and in vivo milestones for cancer over the next 12-months. In vivo data are expected to support discussions with pharmaceutical companies for potential partnering opportunities in exosome therapeutics. SUBB2M TECHNOLOGY ADVANCING TOWARDS COMMERCIALISATION The SubB2M technology has been analytically and clinically validated to detect breast cancer across all stages (81% sensitivity and 93% specificity), key breast cancer types and subtypes, and is effective for breast cancer monitoring. INOVIQ has initiated discussions with potential partners and key opinion leaders to secure a laboratory partner in the US for commercialisation of the SubB2M-CA15-3 test. Additionally, a scientific paper on SubB2M-CA15-3 has been prepared for submission to an international peer-reviewed scientific journal. The next milestones for the SubB2MCA15-3 test are translation to other high-throughput instrument platforms, additional in-clinic breast cancer monitoring studies and securing a CLIA-accredited laboratory partner in the US for commercialisation of the test as a Laboratory Developed Test in 2025. FUTURE MILESTONES The Company expects to report data readouts across its SubB2M tests, exosome diagnostic and therapeutic programs, as well as commercial progress for its EXO-NET research tools and partnering activities over the next 12 months. CEO’s Report
RkJQdWJsaXNoZXIy MjE2NDg3